<<Disclaimer: Verify this information before applying it to your situation.>>

Dr. Robert Anderson continues to promote a celiac disease vaccine 
currently in development by his Victoria, Australia company, Nexpep.  
Little information is being made available about this gluten peptide-
based vaccine, but phase I trials are supposed to begin in 2008 limited 
to HLA-DQ2 celiac disease patients.  The Nexpep website states:

"The vaccine will include the gluten peptides most commonly 
recognised by T cells in people with celiac disease. This general 
approach has been highly successful in non-human models of immune 
diseases and in people with cat-sensitive asthma. It is also under 
active investigation in Type 1 diabetes, multiple sclerosis and 
rheumatoid arthritis."

From this statement I have pulled together some related abstracts and 
articles which discuss T-cell reactive peptide vaccines (see below).  
These vaccines appear to have shown only limited success in the past.  
They may only lessen symptoms and require repeated injections if they 
work at all.  This approach does not look as promising as the 
Recombinant T-cell Receptor Ligand (RTL) drug immunotherapy being 
developed in Oregon which I previously discussed in my last post. 

----------
Nexpep
< http://www.nexpep.com.au/nex/ >
(See the Science)

----------
Vaccine hope for food disease sufferers
By KAMALA HAYMAN - The Press | Monday, 28 May 2007
< http://www.stuff.co.nz/stuff/4075010a11.html >

----------
Am. J. Respir. Crit. Care Med., Vol 154, No. 6, 12 1996, 1623-1628. 
Treatment of cat allergy with T-cell reactive peptides
PS Norman, JL Ohman Jr, AA Long, PS Creticos, MA Gefter, Z Shaked, RA 
Wood, PA Eggleston, KB Hafner, P Rao, LM Lichtenstein, NH Jones and 
CF Nicodemus 
< http://ajrccm.atsjournals.org/cgi/content/abstract/154/6/1623 >

----------
Allergen immunotherapy: therapeutic vaccines for allergic diseases
Geneva: January 2 7—29 1997
< http://www.eaaci.net/media/PDF/W/275.pdf >

----------
Special Feature: Therapeutic intervention in multiple sclerosis: Present 
practice and emerging prospects
Immunology and Cell Biology (1998) 76, 83–90; 
Effects of vaccination with T cell receptor peptides: Epitope switching 
to a possible disease-protective determinant of myelin basic protein 
that is cross-reactive with a TCR BV peptide
Arthur A Vandenbark, Yuan K Chou, Ruth Whitham, Dennis N 
Bourdette, and Halina Offner
< http://www.nature.com/icb/journal/v76/n1/full/icb199810a.html >

----------
Arthritis & Rheumatism Volume 41, Issue 11 , Pages 1919 - 1929
T cell receptor peptide vaccination in rheumatoid arthritis: A placebo-
controlled trial using a combination of V3, V14, and V17 Peptides 
Larry W. Moreland, Elizabeth E. Morgan, Thomas C. Adamson III, 
Zdenka Fronek, Leonard H. Calabrese, Joseph M. Cash, Joseph A. 
Markenson, Alan K. Matsumoto, Joan Bathon, Eric L. Matteson, Kristine 
M. Uramoto, Cornelia M. Weyand, William J. Koopman, Louis W. Heck, 
Vibeke Strand, Jocelyn P. Diveley, Dennis J. Carlo, Christopher J. Nardo, 
Steven P. Richieri, Steven W. Brostoff
(Paste link together on 1 line.)
< http://www3.interscience.wiley.com/cgi-
in/abstract/85008837/ABSTRACT >

----------
PNAS, Apr 15 1991; 88 (8), 3088-3091
Vaccination Against Autoimmune Mouse Diabetes with a T-Cell Epitope 
of the Human 65-kDa Heat Shock Protein
D Elias, T Reshef, OS Birk, R van der Zee, MD Walker and IR Cohen 
< http://www.pnas.org/cgi/content/abstract/88/8/3088 >

* * *

Visit the Celiac Web Page at Http://www.enabling.org/ia/celiac/index.html
Archives are at: Http://Listserv.icors.org/SCRIPTS/WA-ICORS.EXE?LIST=CELIAC